Gilead Sciences, Inc.

The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

* GSK up against competition from Gilead's 3-drug combo (Releads, adds background on rivalry with Gilead)

The U.S. Centers for Medicare and Medicaid Services (CMS) on Wednesday said it has finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc <GILD.O> and Novartis AG <NOVN.S>.

Gilead Sciences Inc <GILD.O> hopes to soon introduce a pricey new pill to prevent HIV in people at risk of contracting the infection, but the drugmaker faces opposition from an unusual source: patient advocates.

An FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.

Independent experts on an FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.

Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by Gilead Sciences Inc and Novartis AG, new data shows, helping explain why sales of the two products have not met rosy expectations.

Gilead Sciences Inc <GILD.O> beat Wall Street estimates for second-quarter revenue and profit on Tuesday, driven by higher sales of HIV treatments, and the U.S. drugmaker raised its full-year sales forecast.

Gilead Sciences Inc reported a 3.5% rise in quarterly profit on Tuesday, as higher sales of its HIV drugs cushioned sluggish demand for its flagship hepatitis C treatments.

* GILEAD SCIENCES LICENSES RESPIRATORY AND HERPES ANTIVIRAL RESEARCH PROGRAMS FROM NOVARTIS

(This July 10 story corrects to show patients switched from Gilead's Descovy, not Gilead's Vemlidy, in fifth paragraph)

GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage study, the drugmaker said on Wednesday.

U.S. antiviral drugmaker Gilead Sciences <GILD.O> will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV <GLPG.AS>, news that lifted Galapagos's shares more than 18% to an all-time high on Monday.

U.S. antiviral drugmaker Gilead Sciences <GILD.O> will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV <GLPG.AS>.

Gilead Sciences Inc will increase its stake in Galapagos NV and gain rights outside Europe to the Belgian-Dutch biotech firm's treatments in development in a $5.1 billion deal, the Wall Street Journal reported on Sunday.

A federal appeals court on Tuesday was considering whether to reinstate a $2.54 billion jury verdict Merck & Co Inc won against Gilead Sciences Inc in a dispute over hepatitis C treatments — the largest ever in a patent infringement case.

Gilead Sciences Inc, which hired Roche veteran Daniel O'Day to be its new chief executive, on Thursday said Kite Pharma, the cancer-focused cell therapy company it acquired in 2017, will become a separate business unit.

Gilead Sciences Inc on Thursday reported a higher first-quarter profit as sales of its important HIV and hepatitis C drugs were largely in line with Wall Street estimates.

Gilead Sciences Inc's experimental drug aimed at treating a type of fatty liver disease known as NASH failed to meet the main goal of a late-stage study on Thursday, two months after it failed another trial.